Literature DB >> 9951562

Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives.

M Leboyer1, A Philippe, M Bouvard, M Guilloud-Bataille, D Bondoux, F Tabuteau, J Feingold, M C Mouren-Simeoni, J M Launay.   

Abstract

BACKGROUND: Whole blood serotonin (5-HT) and C-terminally directed beta-endorphin protein immunoreactivity (C-ter-beta-EP-ir) are known to be elevated in autistic subjects and might be possible markers of genetic liability to autism. This study thus investigates the familial aggregation of 5-HT and of C-ter-beta-EP-ir levels in first degree relatives of autistic probands.
METHODS: In a sample of 62 autistic subjects and 122 of their first-degree relatives, compared to age and sex-matched controls, we measured 5-HT by radioenzymology and C-ter-beta-EP-ir by radioimmunoassay.
RESULTS: We confirm the previously reported familiality of hyperserotoninemia in autism as mothers (51%), fathers (45%) and siblings (87%) have elevated levels of 5-HT, and we reveal presence of elevated levels of C-ter-beta-EP-ir in mothers (53%) of autistic subjects.
CONCLUSIONS: Familial aggregation of quantitative variables, such as concentration of neurotransmitters, within unaffected relative could serve as an intermediate phenotype and might thus help the search of genetic susceptibility factors in autism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9951562     DOI: 10.1016/s0006-3223(97)00532-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  45 in total

Review 1.  The pathophysiology and treatment of autism.

Authors:  D J Posey; C J McDougle
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

2.  Disordered porphyrin metabolism: a potential biological marker for autism risk assessment.

Authors:  Nicholas J Heyer; Diana Echeverria; James S Woods
Journal:  Autism Res       Date:  2012-02-01       Impact factor: 5.216

3.  Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems.

Authors:  Elizabeth Hammock; Jeremy Veenstra-VanderWeele; Zhongyu Yan; Travis M Kerr; Marianna Morris; George M Anderson; C Sue Carter; Edwin H Cook; Suma Jacob
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-05-26       Impact factor: 8.829

Review 4.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

5.  Serotonin transporter gene polymorphisms and hyperserotonemia in autistic disorder.

Authors:  C Betancur; M Corbex; C Spielewoy; A Philippe; J L Laplanche; J M Launay; C Gillberg; M C Mouren-Siméoni; M Hamon; B Giros; M Nosten-Bertrand; M Leboyer
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 6.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

7.  Beta-endorphin levels in longtailed and pigtailed macaques vary by abnormal behavior rating and sex.

Authors:  Carolyn M Crockett; Gene P Sackett; Curt A Sandman; Aleksandra Chicz-DeMet; Kathleen L Bentson
Journal:  Peptides       Date:  2007-07-19       Impact factor: 3.750

Review 8.  Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.

Authors:  S M Francis; A Sagar; T Levin-Decanini; W Liu; C S Carter; S Jacob
Journal:  Brain Res       Date:  2014-01-22       Impact factor: 3.252

Review 9.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

10.  Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder.

Authors:  Sylvie Tordjman; George M Anderson; Michel Botbol; Sylvie Brailly-Tabard; Fernando Perez-Diaz; Rozenn Graignic; Michèle Carlier; Gérard Schmit; Anne-Catherine Rolland; Olivier Bonnot; Séverine Trabado; Pierre Roubertoux; Guillaume Bronsard
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.